-->
It may be time to return to the old-fashioned standard when it comes to treating infertility in women with polycystic ovary syndrome. A recent multicenter, randomized trial involving 626 women finds that clomiphene citrate is three times better than metformin at achieving a live birth in infertile women with the condition, but that it's also about six times more likely to produce a multiple birth.
Researchers calculated a live-birth rate of 22.5% for a group of women taking clomiphene citrate plus placebo, 7.2% for a group taking extended-release metformin plus placebo, and 26.8% for a group of women taking a combination of the two active agents. The rates of multiple pregnancy for the three groups, respectively, were 6.0%, 0%, and 3.1%, while the rates of conception for the three groups were 39.5%, 21.7%, and 46%, respectively. Rates of first-trimester pregnancy loss and adverse events did not differ significantly between the three groups, although gastrointestinal side effects were more frequent, and vasomotor and ovulatory symptoms were less frequent, in the metformin group than in the clomiphene group.
The author of an accompanying editorial points out that the results of this latest study indicate that the combination of clomiphene and metformin provides no greater benefit than clomiphene alone because while the ovulation rate was higher in the combination group, it did not translate into a higher live-birth rate.
Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551-566.
Guzick DS. Treating the polycystic ovary syndrome the old-fashioned way. N Engl J Med. 2007;356:622-624.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More